MedTrace Logo

Implications of Amyloid Pathology

NCT00900770 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2009-12-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether asymptomatic older individuals with high amyloid burden will subsequently manifest cognitive impairment and eventually progress to clinical Alzheimer's Disease (AD).

Conditions

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Reisa Sperling, MD · Director of Clinical Research, Memory Disorders Unit, Brigham and Women's Hospital

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00900770 on ClinicalTrials.gov